Newswire (Published: Monday, March 6, 2017, Received: Thursday, March 2, 2017, 12:12:01 PM CST)
Word Count: 529
Study Data from University of Michigan Update Understanding of Prostate Cancer (American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer)
By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Oncology - Prostate Cancer have been presented. According to news originating from Ann Arbor, Michigan, by NewsRx correspondents, research stated, "To review outcomes for high-risk prostate cancer treated with combined modality radiation therapy (CMRT) utilizing external beam radiation therapy (EBRT) with a brachytherapy boost. The available literature for high-risk prostate cancer treated with combined modality radiation therapy was reviewed and summarized."
Our news journalists obtained a quote from the research from the University of Michigan, "At this time, the literature suggests that the majority of high-risk cancers are curable with multimodal treatment. Several large retrospective studies and three prospective randomized trials comparing CMRT to dose-escalated EBRT have demonstrated superior biochemical control with CMRT. Longer followup of the randomized trials will be required to determine if this will translate to a benefit in metastasis-free survival, disease-specific survival, and overall survival. Although greater toxicity has been associated with CMRT compared to EBRT, recent studies suggest that technological advances that allow better definition and sparing of critical adjacent structures as well as increasing experience with brachytherapy have improved implant quality and the toxicity profile of brachytherapy. The role of androgen deprivation therapy is well established in the external beam literature for high-risk disease, but there is controversy regarding the applicability of these data in the setting of dose escalation. At this time, there is not sufficient evidence for the omission of androgen deprivation therapy with dose escalation in this population. Comparisons with surgery remain limited by differences in patient selection, but the evidence would suggest better disease control with CMRT compared to surgery alone. Due to a series of technological advances, modern combination series have demonstrated unparalleled rates of disease control in the high-risk population."
According to the news editors, the research concluded: "Given the evidence from recent randomized trials, combination therapy may become the standard of care for high-risk cancers."
For more information on this research see: American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy, 2017;16(1):1-12. Brachytherapy can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Brachytherapy - www.journals.elsevier.com/brachytherapy/)
The news correspondents report that additional information may be obtained from P.W. McLaughlin, University of Michigan, Dept. of Radiat Oncol, Ann Arbor, MI 48109, United States. Additional authors for this research include P.D. Soni, P.W. McLaughlin, G.S. Merrick, R.G. Stock, J.C. Blasko and M.J. Zelefsky (see also Oncology - Prostate Cancer).
Keywords for this news article include: Ann Arbor, Michigan, United States, North and Central America, Clinical Trials and Studies, Drugs and Therapies, Post-Trial Research, Prostatic Neoplasms, Radiation Therapy, Clinical Research, Prostate Cancer, Brachytherapy, Radiotherapy, Oncology, Surgery, University of Michigan.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
University of Michigan
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies